Form 4: Tenaya Therapeutics Director Deepak Srivastava Granted 107,400 Stock Options Under Equity Incentive Plan

Deepak Srivastava, a Director at Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options with an exercise price of $0.4444, vesting in May 2026.

Summary

• Deepak Srivastava, a Director of Tenaya Therapeutics, Inc. (TNYA), acquired 107,400 stock options.
• The transaction date for this grant was May 29, 2025.
• The exercise price for these stock options is $0.4444 per share.
• The options were granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.
• The options will vest in full on May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date.
• Vesting is subject to Mr. Srivastava continuing to be a service provider to the Issuer through each applicable vesting date.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Mr. Srivastava beneficially owns 107,400 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it represents a standard and expected compensation event that aligns director interests with shareholders. It does not, however, indicate any new operational or financial breakthroughs.

Positives

• The grant of stock options aligns the director's long-term interests with those of the shareholders, incentivizing performance and value creation.
• The exercise price of $0.4444 is relatively low, potentially offering significant upside if the company's stock price appreciates.

Negatives

• No direct negatives are apparent from this routine compensation disclosure.

Risks

• The value of the stock options is dependent on the future performance of Tenaya Therapeutics' stock price; if the stock price does not exceed the exercise price, the options may expire worthless.
• Vesting of the options is contingent upon the reporting person's continued service to the company, posing a risk if service is terminated prior to vesting.

Future Outlook

The grant of stock options with a future vesting date indicates an expectation of continued service from the director and aligns their incentives with the company's long-term performance and shareholder value creation.

Management Comments

• The stock option was granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages. This practice aims to align the interests of leadership with the long-term success and shareholder value of the company, particularly in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across the biotech and broader corporate landscape, comparable to compensation structures at companies like Sarepta Therapeutics or CRISPR Therapeutics, which also utilize equity incentives to retain and motivate key personnel.
• The vesting schedule, tied to continued service and annual meetings, is typical for such grants, ensuring ongoing commitment from the director.
• The specific exercise price and number of options are company-specific and depend on factors like the company's valuation, compensation philosophy, and the director's role, making direct numerical comparisons without broader context less meaningful.

Corporate Governance

Related Party Transactions

• The grant of stock options to Deepak Srivastava, a Director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the company's value increases.
• Employees: While not directly impacting all employees, the use of an equity incentive plan signals a commitment to performance-based compensation, which can positively influence overall company culture and talent retention strategies.

Next Steps

• The stock options will vest in full on May 29, 2026, or earlier if the next annual meeting of stockholders occurs before that date, subject to continued service.
• Deepak Srivastava may choose to exercise these options at any time after vesting and before the expiration date of May 28, 2035.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Stock Option, Equity Incentive Plan, Director Compensation, SEC Form 4, Deepak Srivastava, Insider Transaction, Beneficial Ownership